Assessment of atherothrombosis and its treatment in Mexico: first-year data of the REACH Registry.

Clinical Cardiology
Efraín GaxiolaReduction of Atherothrombosis for Continued Health Registry Investigators

Abstract

Atherothrombosis, a generalized and progressive process, is currently a major healthcare problem in Mexico. The worldwide Reduction of Atherothrombosis for Continued Health (REACH) registry aimed to evaluate risk factors for atherosclerosis, long-term cardiovascular (CV) event rates, and current management of either patients with established symptomatic atherosclerotic disease or asymptomatic subjects with multiple risk factors for atherothrombotic disease. One-year follow-up of the global REACH database was available for 64 977 outpatients. This report includes the Mexican subregistry wherein 62 internists, cardiologists, and neurologists evaluated baseline patient characteristics, risk factors, medications, and CV event rates as primary outcomes at 1-year follow-up. Complete 1-year follow-up data were available for 837 Mexicans. We observed a high prevalence of diabetes (47.1%), hypertension (74.7%), and hypercholesterolemia (57.8%). Antiplatelet, antihypertensive and/or glucose-lowering agents, and lipid-lowering drugs were used in 87.6%, 84.1%, and 61% of patients, respectively. The all-cause mortality rate was 3.3%. The composite outcome CV death/myocardial infarction/stroke/hospitalization for atherothrombotic events was ...Continue Reading

References

Jan 1, 1982·Journal of Chronic Diseases·I M ChangM Pagano
Jun 1, 1995·Arteriosclerosis, Thrombosis, and Vascular Biology·B D MitchellM P Stern
Feb 24, 2000·The Medical Clinics of North America·D L Bhatt, E J Topol
Sep 19, 2001·JAMA : the Journal of the American Medical Association·A T HirschW R Hiatt
Jan 23, 2002·Cerebrovascular Diseases·Dirk W Droste, E Bernd Ringelstein
Sep 11, 2003·European Heart Journal·Guy De BackerUNKNOWN Third Joint Task Force of European and Other Societies on Cardiovascular Disease Prevention in Clinical Practice
Jan 13, 2006·JAMA : the Journal of the American Medical Association·Deepak L BhattUNKNOWN REACH Registry Investigators
Mar 22, 2007·JAMA : the Journal of the American Medical Association·Ph Gabriel StegUNKNOWN REACH Registry Investigators
Dec 19, 2007·Circulation·Wayne RosamondUNKNOWN American Heart Association Statistics Committee and Stroke Statistics Subcommittee
Jan 12, 2008·The American Journal of Medicine·Herman SchargrodskyUNKNOWN CARMELA Study Investigators
Mar 1, 2008·Journal of the American College of Cardiology·Javier SanzValentin Fuster

❮ Previous
Next ❯

Citations

Jun 2, 2012·Clinical Cardiology·Carlos Cantú-BritoUNKNOWN REACH Latin America Collaborative Group

❮ Previous
Next ❯

Related Concepts

Related Feeds

Antihypertensive Agents: Mechanisms of Action

Antihypertensive drugs are used to treat hypertension (high blood pressure) which aims to prevent the complications of high blood pressure, such as stroke and myocardial infarction. Discover the latest research on antihypertensive drugs and their mechanism of action here.

Carotid Artery Diseases

Carotid artery disease is a group of pathological conditions of the carotid artery. Discover the latest research on carotid artery disease here.

Cardiovascular Disease Pathophysiology

Cardiovascular disease involves several different processes that contribute to the pathological mechanism, including hyperglycemia, inflammation, atherosclerosis, hypertension and more. Vasculature stability plays a critical role in the development of the disease. Discover the latest research on cardiovascular disease pathophysiology here.

Cardiovascular Disorder in Diabetes

Diabetes is associated with an increased risk of cardiovascular disorders and heart failure. Discover the latest research here.

Atherosclerosis Disease Progression

Atherosclerosis is the buildup of plaque on artery walls, causing stenosis which can eventually lead to clinically apparent cardiovascular disease. Find the latest research on atherosclerosis disease progression here.